Cite
HARVARD Citation
Aliprantis, A. et al. (2021). A Phase 1 Randomized, Double‐Blind, Placebo‐Controlled Trial to Assess the Safety, Tolerability, and Pharmacokinetics of a Respiratory Syncytial Virus Neutralizing Monoclonal Antibody MK‐1654 in Healthy Adults. Clinical pharmacology in drug development. 10 (5), pp. 556-566. [Online].